1. Home
  2. AIRS vs PROF Comparison

AIRS vs PROF Comparison

Compare AIRS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIRS

AirSculpt Technologies Inc.

HOLD

Current Price

$4.14

Market Cap

169.8M

Sector

Health Care

ML Signal

HOLD

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$7.18

Market Cap

243.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRS
PROF
Founded
2012
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Nursing Services
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
169.8M
243.2M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
AIRS
PROF
Price
$4.14
$7.18
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
1.3M
84.0K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.89
EPS
N/A
0.19
Revenue
$151,818,000.00
$16,098,000.00
Revenue This Year
$5.19
$92.40
Revenue Next Year
$5.32
$64.10
P/E Ratio
N/A
$37.74
Revenue Growth
N/A
50.73
52 Week Low
$1.51
$3.92
52 Week High
$12.00
$8.95

Technical Indicators

Market Signals
Indicator
AIRS
PROF
Relative Strength Index (RSI) 71.04 57.00
Support Level $2.40 $7.00
Resistance Level $6.90 $7.97
Average True Range (ATR) 0.37 0.46
MACD 0.15 0.02
Stochastic Oscillator 80.63 48.92

Price Performance

Historical Comparison
AIRS
PROF

About AIRS AirSculpt Technologies Inc.

AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: